[{"id":"e41df1b0-a381-4409-acf3-86d752328c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472933","created_at":"2026-03-28T01:36:46.537Z","updated_at":"2026-03-28T01:36:46.537Z","phase":"Phase 2","brief_title":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","source_id_and_acronym":"NCT07472933","lead_sponsor":"West China Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2026-03-18"},{"id":"f43e758f-4bc3-4256-ae14-899721a6e9b8","acronym":"GALENT-BT","url":"https://clinicaltrials.gov/study/NCT06963060","created_at":"2025-09-07T01:31:36.203Z","updated_at":"2025-09-07T01:31:36.203Z","phase":"Phase 2","brief_title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","source_id_and_acronym":"NCT06963060 - GALENT-BT","lead_sponsor":"Wei Gong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 44","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-05-08"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"9ae6d61c-52ac-447d-9656-ee355853d0dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04068194","created_at":"2023-11-15T17:14:49.418Z","updated_at":"2025-02-25T13:52:57.960Z","phase":"Phase 1/2","brief_title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","source_id_and_acronym":"NCT04068194","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"e403d404-bc05-4817-9ff3-f97c2077e32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03449381","created_at":"2021-01-18T17:00:34.045Z","updated_at":"2025-02-25T14:15:08.572Z","phase":"Phase 1","brief_title":"This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT03449381","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-18"},{"id":"51bfec9e-786f-4114-83f4-e740501ef39e","acronym":"KEYNOTE-E34","url":"https://clinicaltrials.gov/study/NCT05784688","created_at":"2023-03-27T20:03:27.380Z","updated_at":"2025-02-25T14:09:34.861Z","phase":"Phase 1/2","brief_title":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05784688 - KEYNOTE-E34","lead_sponsor":"TiumBio Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type","tags":["EGFR • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tosposertib (NCE 401)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-17"},{"id":"360b90be-2213-4d23-b6e5-cc0f96b7a6e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238715","created_at":"2021-01-19T19:12:02.961Z","updated_at":"2025-02-25T14:40:28.907Z","phase":"Phase 2","brief_title":"A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion","source_id_and_acronym":"NCT04238715","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-14"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2025-02-25T15:26:28.507Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-10"},{"id":"a46eecea-cdfb-4325-ac71-c96ea8e37386","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823311","created_at":"2023-04-21T15:04:25.336Z","updated_at":"2025-02-25T15:20:26.716Z","phase":"Phase 3","brief_title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05823311","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"f87d079d-5408-46e1-abc8-978710f92fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05532059","created_at":"2022-09-08T13:55:00.765Z","updated_at":"2025-02-25T15:27:37.097Z","phase":"Phase 2","brief_title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05532059","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-10"},{"id":"fc5b6895-f7f7-4459-b71c-62a35c47f883","acronym":"ProvIDHe","url":"https://clinicaltrials.gov/study/NCT05876754","created_at":"2023-05-25T15:05:46.429Z","updated_at":"2025-02-25T15:20:32.101Z","phase":"Phase 3","brief_title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05876754 - ProvIDHe","lead_sponsor":"Servier Affaires Médicales","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-10"},{"id":"091b04f6-47ba-4538-8841-468728890fac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05211323","created_at":"2023-08-01T14:09:13.778Z","updated_at":"2025-02-25T16:32:43.506Z","phase":"Phase 2","brief_title":"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer","source_id_and_acronym":"NCT05211323","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"5f277fe7-343a-4221-8527-c095bdf402da","acronym":"","url":"https://clinicaltrials.gov/study/NCT04175912","created_at":"2021-01-29T07:20:00.803Z","updated_at":"2025-02-25T16:37:37.268Z","phase":"Phase 2","brief_title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","source_id_and_acronym":"NCT04175912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • UBE2M • NEDD8","pipe":"","alterations":" ","tags":["CD4 • UBE2M • NEDD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 11/27/2023","primary_completion_date":" 11/27/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"235d782d-2e73-4b08-9fbb-54173c4ba4b6","acronym":"HERBOT","url":"https://clinicaltrials.gov/study/NCT05749900","created_at":"2023-03-01T15:02:12.876Z","updated_at":"2025-02-25T16:46:38.516Z","phase":"Phase 1/2","brief_title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","source_id_and_acronym":"NCT05749900 - HERBOT","lead_sponsor":"Yonsei University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-05"},{"id":"af4c7cda-c517-4da6-b8c2-a10bb4a3610e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04100694","created_at":"2021-01-18T20:03:38.689Z","updated_at":"2025-02-25T16:44:42.630Z","phase":"","brief_title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","source_id_and_acronym":"NCT04100694","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bizengri (zenocutuzumab-zbco)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-05"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"9d94409b-3124-4594-8d29-7cfddaf92a43","acronym":"FOENIX-CCA4","url":"https://clinicaltrials.gov/study/NCT05727176","created_at":"2023-02-14T18:02:28.005Z","updated_at":"2025-02-25T17:02:23.376Z","phase":"Phase 2","brief_title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","source_id_and_acronym":"NCT05727176 - FOENIX-CCA4","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-03"},{"id":"ef460ada-1956-4c98-ae47-6b4d433dca90","acronym":"ReFocus","url":"https://clinicaltrials.gov/study/NCT04526106","created_at":"2021-01-18T21:40:34.651Z","updated_at":"2025-02-25T17:30:23.437Z","phase":"Phase 1/2","brief_title":"REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors","source_id_and_acronym":"NCT04526106 - ReFocus","lead_sponsor":"Elevar Therapeutics","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lirafugratinib (RLY-4008)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-30"}]